Floatz logo

Lipitor

PTC

Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the PTC cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Cobimetinib
Cancer Research UK
Phase 2/3B
gsk1120212
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC

View all 31 →

Same molecule, other indications

Lipitor is also rated in:

inherited lipid metabolism disorderDormant
A
Indicative ·
83 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative ·
79 / 100
View asset →
HypercholesterolemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →